Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.

The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.

The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.

CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.